Great reminder that BOT’s acne product works. Obviously there were some issues with the vehicle in the USA which we will never know the full details of, but this does not mean that 1801 is a failure, this company is way over sold.
Matt’s interview indicates the company fully supports the efficacy of the product. They are going to phase 3 with this, the FDA meeting is not for phase 3 approval it is to find out how many participants and for how long the trial needs to go for. Then it is off to the multibillion dollar market $$$.
Antimicrobial platform - BTX 1801 Phase 2a clinical study, page-74
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.020(6.25%) |
Mkt cap ! $615.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 34.0¢ | 32.0¢ | $1.776M | 5.339M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 118187 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 698385 | 8 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |